Sun Pharmaceutical vs Laurus Labs: share price, P/E, ROE and financials compared
Sun Pharmaceutical Industries
Laurus Labs
Sun Pharmaceutical and Laurus Labs at a glance
Sun Pharmaceutical and Laurus Labs are both listed in Healthcare. Sun Pharmaceutical is the larger by market cap, at ₹4.5L Cr against ₹1.3L Cr for Laurus Labs (3.5 times as large). On valuation, Sun Pharmaceutical has the lower P/E (40.7× against 94.4×) and the lower price-to-book (4.99× against 20.86×). On returns and margins, Laurus Labs has the higher ROCE (19.5% against 17.9%), the higher ROE (24.0% against 13.1%) and the higher operating margin (30.4% against 28.2%). Over three years, Sun Pharmaceutical has faster 3-year sales growth (+10.4% against +3.8% a year) and faster 3-year profit growth (+10.6% against +4.0% a year). Sun Pharmaceutical carries less debt for its equity, with a debt-to-equity of 0.04× against 0.42×.
Key metrics, side by side
| Metric | Sun PharmaceuticalSUNPHARMA | Laurus LabsLAURUSLABS |
|---|---|---|
| Price (₹) | 1,860.00 | 2,340.00 |
| Market cap (₹ Cr) | 4,46,276 | 1,26,433 |
| P/E | 40.7× (the lower figure, shaded) | 94.4× |
| P/B | 4.99× (the lower figure, shaded) | 20.86× |
| Dividend yield, trailing | 0.86% (the higher figure, shaded) | 0.05% |
| ROE | 13.1% | 24.0% (the higher figure, shaded) |
| ROCE | 17.9% | 19.5% (the higher figure, shaded) |
| Operating margin (OPM) | 28.2% | 30.4% (the higher figure, shaded) |
| Net margin (NPM) | 17.8% (the higher figure, shaded) | 17.1% |
| Sales CAGR 3Y | +10.4% (the higher figure, shaded) | +3.8% |
| Profit CAGR 3Y | +10.6% (the higher figure, shaded) | +4.0% |
| Debt to equity | 0.04× (the lower figure, shaded) | 0.42× |
| Interest cover | 45.6× (the higher figure, shaded) | 8.3× |
| Net profit TTM (₹ Cr) | 10,966 | 1,340 |
| 1Y return | +8.2% | +138.6% (the higher figure, shaded) |
| Promoter holding | – | – |
Sun Pharmaceutical vs Laurus Labs: common questions
Which is bigger, Sun Pharmaceutical or Laurus Labs?
By market cap, Sun Pharmaceutical is bigger at ₹4.5L Cr, against ₹1.3L Cr for Laurus Labs (prices as of 6 Nov 2026). Net profit over the last twelve months was ₹10,966 Cr for Sun Pharmaceutical and ₹1,340 Cr for Laurus Labs.
Which has a lower P/E ratio, Sun Pharmaceutical or Laurus Labs?
Sun Pharmaceutical trades at a P/E of 40.7× and Laurus Labs at 94.4×. Sun Pharmaceutical has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Sun Pharmaceutical or Laurus Labs?
Sun Pharmaceutical reports a return on equity of 13.1% and Laurus Labs 24.0%. Laurus Labs has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Sun Pharmaceutical or Laurus Labs?
Over the last three years: Sales grew +10.4% a year at Sun Pharmaceutical and +3.8% at Laurus Labs, so Sun Pharmaceutical grew sales faster; profit grew +10.6% a year at Sun Pharmaceutical and +4.0% at Laurus Labs, so Sun Pharmaceutical grew profit faster. Past growth doesn’t predict future growth.